Complain about a product or service

FDA Clears New Breast Cancer Test

MammaPrint Determines Likelihood Cancer Will Recur

February 7, 2007

Breast Cancer • Recommended Changes to Breast Cancer Screenings Cause Controversy • Optical Biopsy Provides Surgery-Free Diagnosis • Breast Cancer Lawsuit Alleged Needless Suffering, Death • New Chemo Cocktail Blocks Breast Cancer 'Like A Fence' • Physically Fit Women Less Likely To Die Of Breast Cancer • No Link Found Between Caffeine and Breast Cancer Risk • Older Women at Greater Risk of Breast Cancer • Companies Agree To Cut Cancer-Causing Chemicals In Potato Chips • What Women -- and Men -- Should Know about Breast Cancer • Daily Aspirin May Reduce Risk of Breast Cancer • FDA Approves New Genetic Test for Breast Cancer • Gene Mutation Spreads Breast Cancer • Research Finds Green Tea Helpful Against Breast Cancer • Marijuana Compound May Fight Breast Cancer • Mayo Clinic Sees New Hope In Breast Cancer Drug • FDA Approves Evista For Reducing Breast Cancer Risk • Side Effects Drive Women from Breast Cancer Drug • Hypnosis Reduces Pain and Costs in Breast Cancer Surgery • Grapefruit Linked to Breast Cancer • Study Finds No Link Between Abortion, Miscarriage and Breast Cancer • Falling Breast Cancer Rates Linked to Declining Use of Hormone Replacement Therapy • Hispanic Women Three Times More Likely to Develop Advanced Breast Cancer • MRI Screening of Opposite Breast Necessary for Women with Breast Cancer • FDA Approves Tykerb for Advanced Breast Cancer Patients • FDA Clears New Breast Cancer Test • Needle Biopsy May Not Be Enough to Rule Out Breast Cancer in Some Cases • Red Meat May Increase Breast Cancer Risk • Breast Cancer Survivors Skipping Mammograms, Study Finds • Breast Implant Complications Frequent, Study Finds • Tests Show Drug Fights Aggressive Breast Cancer • California Sues to Require Cancer Warnings on Potato Chips and French Fries • Study Ties Fries To Breast Cancer Risk • Low-Fat Diet May Reduce Risk of Recurrent Breast Cancer • Study Suggests Pain Reliever, Breast Cancer Link • Trials Show Herceptin Aids Breast Cancer Recovery • That Pink Ribbon Can Be Misleading, Consumer Group Warns • Survival Better When Breast Cancer Detected Through Mammography

The U.S. Food and Drug Administration (FDA) has cleared for marketing a test that determines the likelihood of breast cancer returning within five to 10 years after a woman's initial cancer. It is the first cleared molecular test that profiles genetic activity.

The MammaPrint test uses the latest in molecular technology to predict whether existing cancer will metastasize and spread to other parts of a patient's body. The test relies on microarray analysis, a powerful tool for simultaneously studying the patterns of behavior of large numbers of genes in biological specimens.

The recurrence of cancer is partly dependent on the activation and suppression of certain genes located in the tumor. Prognostic tests like the MammaPrint can measure the activity of these genes, and thus help physicians understand their patients' odds of the cancer spreading.

MammaPrint was developed by Agendia, a laboratory located in Amsterdam, Netherlands, where the product has been on the market since 2005.

"Clearance of the MammaPrint test marks a step forward in the initiative to bring molecular-based medicine into current practice," said Andrew C. von Eschenbach, M.D., Commissioner of Food and Drugs. "MammaPrint results will provide patients and physicians with more information about the prospects for the outcome of the disease. This information will support treatment decisions.

Agendia compared the genetic profiles of a large number of women suffering from breast cancer and identified a set of 70 genes whose activity confers information about the likelihood of tumor recurrence.

The MammaPrint test measures the level of activity of each of these genes in a sample of a woman's surgically removed breast cancer tumor, then uses a specific formula, known as an algorithm, to produce a score that determines whether the patient is deemed low risk or high risk for spread of the cancer to another site. The result may help a doctor in planning appropriate follow-up for a patient when used with other clinical information and laboratory tests.

The MammaPrint is the first cleared in vitro diagnostic multivariate index assay (IVDMIA) device. Several months ago, FDA issued a draft guidance document concerning the need for these complex molecular tests to meet pre-market review and post-market device requirements even when the tests are developed and used by a single laboratory.

Although FDA regulates diagnostic tests sold to laboratories, hospitals and physicians, it uses discretion when regulating tests developed and performed by single laboratories.

"There have been rapid advances in microarrays and other pioneering diagnostics, and a corresponding increase in the use and impact of these complex tests. This has prompted FDA to take a closer look at the potential risks as well as the benefits associated with such tests when they are developed and used in laboratories," remarked Steven Gutman, M.D., Director, Office of In Vitro Diagnostic Device Evaluation.

"This test clearance takes into account the development of these innovative technologies and ensures public health by carefully evaluating their performance."

Prior to clearance, FDA requested evidence that the MammaPrint had been properly validated for its intended use. Agendia submitted data from a study using tumor samples and clinical data from 302 patients at five European centers.

These studies confirmed that the test was useful in predicting time to distant metastasis in women who are under age 61 and in the two earliest stages of the disease (Stage I and Stage II) and who have tumor size equal to or less than five centimeters and no evidence that the cancer has spread to nearby lymph nodes (lymph node negative).

According to the American Cancer Society, an estimated 178,480 new cases of invasive breast cancer will be diagnosed among women in the United States this year and over 40,000 women are expected to die from the disease.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.